Alwin Capital

What Alwin Capital does

Alwin Capital (北京雅惠资产管理有限公司 / 雅惠投资) is a Beijing-based, privately held venture capital firm founded in 2015 that specializes exclusively in life science investments in China. The firm manages a dual-currency (RMB and USD) fund family with combined assets under management of approximately $500 million, deploying research-driven, thesis-led capital across five interlocking sub-sectors: Innovative Drugs, Molecular Diagnostics, Innovative Hardware, Scientific Services, and AI Applications. Its portfolio spans roughly 30 companies, several of which are segment leaders — notably 23 MoFang (Direct-to-Consumer genetic testing, ~40% market share), Singleron (single-cell sequencing), Keya Medical (first Chinese AI Class III medical device approval), and Edigene (first Chinese gene therapy IND).

The firm's core team is small and tightly tenured: Yana Sun, PhD, CFA (Founding Partner; former Managing Director at CICC and first healthcare analyst at CICC), Huijing Shi (Founding Partner; former COO of CICC's fund-of-hedge-funds business managing over RMB 5 billion), and Sibo Lin (Executive Director; Tsinghua MBA, Peking University Biology undergraduate). The team works together for more than ten years, providing both scientific due diligence and capital markets expertise — a combination the firm positions as its differentiator versus generalist Chinese VCs.

Alwin's revenue model is the standard venture capital fund manager structure: management fees on committed or invested capital in the RMB and USD funds, plus carried interest on investment returns across the portfolio. The firm has no proprietary technology products, no software offering, and no public marketplace. Capital is sourced bilaterally from institutional and sophisticated LPs and deployed through direct negotiated venture equity transactions. The firm is geographically concentrated in China, with the operating headquarters in Beijing, and shows no disclosed international expansion beyond the USD fund vehicle.

Name

Alwin Capital

Legal name

北京雅惠资产管理有限公司 (Beijing Yahui Asset Management Co., Ltd.)

Website

https://alwincapital.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Alwin Capital is a Beijing-based venture capital firm founded in 2015 that manages ~$500M in dual-currency (RMB and USD) funds, specializing exclusively in early-stage Chinese life science investments across innovative drugs, molecular diagnostics, medtech hardware, scientific services, and AI applications.

Ownership category

akta.pro rank

Product category

Life Science Venture Capital

NAICS

All Other Financial Investment Activities (52399)

SIC

Investment Advice (6282)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

akta.pro secondary industry

Corporate Strategic Real Assets & Infrastructure Venture Investing (FSANAHAN)

Keywords

• Life science venture capital
• Biotech investment funds
• Healthcare venture capital
• Molecular diagnostics investing
• Innovative drug investment

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Fund management fees and carried interest: Alwin Capital operates RMB and USD-denominated life science venture capital funds with approximately $500 million in assets under management. As a fund manager, revenue is generated primarily through management fees on committed/invested capital and carried interest on investment returns across its portfolio of life science companies.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

Alwin Capital is a professional venture capital firm that manages dual-currency (RMB and USD) life science investment funds with approximately $500 million in combined assets under management. The firm invests in early- and growth-stage Chinese life science companies across five thematic areas: Innovative Drugs, Molecular Diagnostics, Innovative Hardware, Scientific Services, and AI Applications. Capital is raised from limited partners and deployed via direct venture equity investments into portfolio companies spanning gene editing, mRNA therapeutics, cell therapy, ADC drugs, tumor liquid biopsy, reproductive health genetics, gene sequencing hardware, and AI medical devices.

Product overview

Alwin Capital operates as a single integrated venture capital platform rather than a multi-module software product, delivering a unified life science investment service through its dual-currency fund (RMB and USD, ~$500 million AUM) founded in 2015. The platform is organized thematically around five interlocking investment areas — Innovative Drugs, Molecular Diagnostics, Innovative Hardware, Scientific Services, and AI Applications — which together constitute the firm's service offering and portfolio structure. The core offering is the Alwin Capital Life Science Investment Fund, with sub-portfolios (Innovative Drugs, Molecular Diagnostics, Innovative Hardware, and AI Applications) representing the distinct thematic allocations through which capital is deployed to portfolio companies.

Differentiator

Problem solved

Functional benefit

Products and services

• Alwin Capital Life Science Investment Fund Dual-currency (RMB and USD) venture capital fund focused on life science investments in China, managing approximately $500 million in assets under management. Targets innovative companies in Innovative Drugs, Molecular Diagnostics, Innovative Hardware, Scientific Services, and AI Applications. Offered to institutional and sophisticated limited partners.
• Innovative Drugs Investment Portfolio Thematic investment allocation within Alwin Capital's life science fund targeting new drug R&D, including gene editing, mRNA drug developers, cell therapy (CAR-T) firms, ADC drug developers, complement drug developers, tumor immunotherapy, and microbiome drug R&D companies.
• Molecular Diagnostics Investment Portfolio Thematic investment allocation within Alwin Capital's life science fund targeting molecular diagnostics, including tumor liquid biopsy, mass spectrometry testing, genetic disease testing, molecular pathology platforms, forensic DNA testing, and DTC gene testing companies.
• Innovative Hardware Investment Portfolio Thematic investment allocation within Alwin Capital's life science fund targeting innovative medical hardware, including high-throughput gene synthesis, third-generation gene sequencing services, ONT nanopore sequencer R&D, digital PCR platforms, surgical robots, orthopedic robotics, neural intervention consumables, and cardiac mechanical circulatory support systems.
• AI Applications Investment Portfolio

Quantifiable outcome

• ~USD 500 million assets under management across RMB and USD life science funds
• +2 more outcomes

Named customers24 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Qiming Venture Partners (Healthcare): Leading Chinese venture capital firm with a dedicated healthcare practice investing in biotech, medical devices, diagnostics, and healthcare services across early and growth stages. Direct peer given China healthcare focus and early-stage investment profile.
• 6 Dimensions Capital: Healthcare-dedicated venture capital firm investing in China life sciences across therapeutics, medical devices, and diagnostics. Direct peer given shared focus on China-based life science opportunities and similar stage profile.
• Highlight Capital (高特佳投资): China-focused healthcare investment firm with early and growth-stage life science investing across pharma, diagnostics, and medical devices. Direct peer given specialized China healthcare mandate and overlapping portfolio categories.
• Lilly Asia Ventures: China-focused life sciences venture capital firm backed by Eli Lilly that invests across therapeutics, diagnostics, and medical devices at early and growth stages. Most comparable peer to Alwin given similar China-only life science mandate, comparable AUM scale, and stage focus.
• Lake Bleu Capital: Hong Kong-based healthcare-dedicated public and private investment manager covering China biotech, pharma services, and medical devices. Direct peer given China healthcare specialization, cross-border RMB/USD capability, and similar early-to-growth stage focus.
• TF Capital (联想之星): Early-stage Chinese venture capital firm with significant healthcare and life sciences practice backed by Legend Holdings. Direct peer given China-only focus and concentration on early-stage life science investments.
• OrbiMed Advisors (Asia): Global healthcare-dedicated investment firm with significant China deployment through its Asia private equity funds investing in pharma, medical devices, and diagnostics. Direct peer in life science specialization with overlapping portfolio categories (oncology, genomics, medical devices).

Broad incumbents

• Sequoia Capital China (Healthcare): China arm of Sequoia Capital with active healthcare practice spanning biotech, medtech, and digital health. Broader incumbent peer given significantly larger AUM and generalist mandate, but overlapping thesis on China life science innovation.
• CDB Capital (国开金融): Chinese state-backed investment platform with significant healthcare and life sciences exposure across venture and growth stages. Broader incumbent peer given larger AUM and broader Chinese investment mandate but overlapping interest in domestic life science innovation.
• Hillhouse Capital (Healthcare): Major Asian investment firm with a dedicated healthcare practice covering innovative drugs, medical devices, and diagnostics in China and globally. Broader incumbent peer given much larger AUM and cross-sector mandate but significant overlap in life science verticals.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments24 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alwin Capital